Page 1,119«..1020..1,1181,1191,1201,121..1,1301,140..»

Category Archives: Transhuman News

Scientists seek insight into Parkinson’s, addiction by tracking gene expression in the brain – MIT News

Posted: January 15, 2021 at 2:28 pm

Two MIT neuroscientists have been awarded grants from the G. Harold and Leila Y. Mathers Foundation to screen for genes that could help brain cells withstand Parkinsons disease and to map how gene expression changes in the brain in response to drugs of abuse.

Myriam Heiman, an associate professor in the Department of Brain and Cognitive Sciences and a core member of The Picower Institute for Learning and Memory and the Broad Institute of MIT and Harvard; and Alan Jasanoff, a professor in biological engineering, brain and cognitive sciences, nuclear science and engineering, and an associate investigator at the McGovern Institute for Brain Research, each received three-year awards that formally began on Jan. 1.

Jasanoff, who also directs MITs Center for Neurobiological Engineering, is known for developing sensors that monitor molecular hallmarks of neural activity in the living brain, in real-time, via noninvasive magnetic resonance imaging (MRI) brain scanning. One of the MRI-detectable sensors that he has developed is for dopamine, a neuromodulator that is key to learning what behaviors and contexts lead to reward. Addictive drugs artificially drive dopamine release, thereby hijacking the brains reward prediction system. Studies have shown that dopamine and drugs of abuse activate gene transcription in specific brain regions, and that this gene expression changes as animals are repeatedly exposed to drugs. Despite the important implications of these neuroplastic changes for the process of addiction, in which drug-seeking behaviors become compulsive, there are no effective tools available to measure gene expression across the brain in real time.

With the new Mathers funding, Jasanoff is developing new MRI-detectable sensors for gene expression. With these cutting-edge tools, Jasanoff proposes to make an activity atlas of how the brain responds to drugs of abuse, both upon initial exposure and over repeated doses that simulate the experiences of drug-addicted individuals.

Our studies will relate drug-induced brain activity to longer-term changes that reshape the brain in addiction, says Jasanoff. We hope these studies will suggest new biomarkers or treatments.

Dopamine-producing neurons in a brain region called the substantia nigra are known to be especially vulnerable to dying in Parkinsons disease, leading to the severe motor difficulties experienced during the progression of the incurable, chronic neurodegenerative disorder. The field knows little about what puts specific cells at such dire risk, or what molecular mechanisms might help them resist the disease. In her research on Huntingtons disease, another incurable neurodegenerative disorder in which a specific neuron population in the striatum is especially vulnerable, Heiman has been able to use an innovative method her lab pioneered to discover genes whose expression promotes neuron survival, yielding potential new drug targets. The technique involves conducting an unbiased screen in which her lab knocks out each of the 22,000 genes expressed in the mouse brain one by one in neurons in disease model mice and healthy controls. The technique allows her to determine which genes, when missing, contribute to neuron death amid disease and therefore which genes are particularly needed for survival. The products of those genes can then be evaluated as drug targets. With the new Mathers award, Heiman plans to apply the method to study Parkinsons disease.

There is currently nomolecular explanation for the brain cell loss seen in Parkinsons disease ora cure for this devastating disease, Heiman says. This award will allow us to perform unbiased, genome-widegenetic screens in the brains of mouse models of Parkinsons disease, probingfor genes that allow brain cells to survive the effects of cellular perturbationsassociated with Parkinsons disease. Im extremely grateful for this generous support and recognition of our work from the Mathers Foundation, and hope that our study will elucidate new therapeutic targets for the treatment, and even prevention, of Parkinsons disease.

Follow this link:
Scientists seek insight into Parkinson's, addiction by tracking gene expression in the brain - MIT News

Posted in Genetic Engineering | Comments Off on Scientists seek insight into Parkinson’s, addiction by tracking gene expression in the brain – MIT News

Global Bacterial and Plasmid Vectors Market Report 2020: Market is Expected to Recover and Reach $0520 Million in 2023 at a CAGR of 15.48% – Forecast…

Posted: at 2:28 pm

Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Bacterial and Plasmid Vectors Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Major players in the bacterial and plasmid vectors market are Sigma-Aldrich Inc., ATUM, QIAGEN, Promega Corporation, Thermo Fisher Scientific, Inc., GenScript Biotech Corporation, Takara Bio Inc., IBA GmbH, Bio-Rad Laboratories and New England Biolabs.

The global bacterial and plasmid vectors market is expected to decline from $0.36 billion in 2019 to $0.34 billion in 2020 at a compound annual growth rate (CAGR) of -7.62%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges. The entire supply chain has been disrupted, impacting the market negatively. The market is then expected to recover and reach $0.52 billion in 2023 at a CAGR of 15.48%.

The bacterial and plasmid vectors market consists of sales of bacterial and plasmid vectors and related services by entities (organizations, sole traders and partnerships) that develop bacterial and plasmid vectors for biotechnological applications. Bacterial vectors are DNA molecules that are the basic tool of genetic engineering and are used to introduce foreign genetic material into a host to replicate and amplify the foreign DNA sequences as a recombinant molecule. The vectors are used for introducing a definite gene into the target cell and command the cell's mechanism for protein synthesis to produce the protein encoded by the gene. These are used for the production of protein in biotechnology applications.

North America was the largest region in the bacterial and plasmid vectors market in 2019. Asia-Pacific is expected to be the fastest-growing region in the forecast period.

In May 2018, Vectalys, a France-based company engaged in manufacturing and commercializing lentiviral vectors for gene delivery, and FlashCell, a company engineering non-integrating lentiviral delivered RNA therapeutics, announced their merger to create a new gene therapy company - Flash Therapeutics.

Flash Therapeutics is expected to collaborate on the two complementary businesses of Vectalys and FlashCell and combine the emergence of cell and gene therapies as major new therapeutic modalities for the treatment of incurable diseases. Flash Therapeutics is a new gene and cell therapy company based in Occitanie, France engaged in developing gene and cell-based therapies by leveraging its bioproduction technologies and lentiviral platform.

The high cost of gene therapy is expected to limit the growth of the bacterial and plasmid vectors market during the forecast period. The cost of gene therapy treatments approved by the Food and Drug Administration is between $0.3 million and $2.1 million. Moreover, the cost of Luxturna gene therapy for certain inherited retinal diseases (IRDs) is $0.4 million per eye and LentiGlobin, a gene therapy by Bluebird Bio designed to increase the levels of hemoglobin, costs around $2.1 million. Stringent government regulations, long approval processes, and high production costs are the major factors leading to the high cost of gene therapy. Thus, the high cost of gene therapy is expected to hinder the growth of the bacterial and plasmid vectors market in the near future.

The focus areas for many companies in the bacterial and plasmid vectors market has shifted to mergers and acquisitions to enhance production capabilities. Large prime manufactures are forming joint ventures or buying small or midsized companies to acquire new capabilities or to gain access to new markets.

The increasing prevalence of cancer and infectious diseases is anticipated to boost the demand for the bacterial and plasmid vectors market over the coming years. Bacterial vectors are used for the delivery of recombinant proteins into target cells for the treatment of cancer and various infectious diseases. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, responsible for an estimated 9.6 million deaths in 2018.

The growing prevalence of cancer and various infectious diseases and the increasing demand for bacterial and plasmid vectors for gene therapy are projected to propel the market revenues for the bacterial and plasmid vectors market.

Key Topics Covered:

1. Executive Summary

2. Bacterial and Plasmid Vectors Market Characteristics

3. Bacterial and Plasmid Vectors Market Size and Growth 3.1. Global Bacterial and Plasmid Vectors Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers of the Market 3.1.2. Restraints on the Market 3.2. Global Bacterial and Plasmid Vectors Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers of the Market 3.2.2. Restraints on the Market

4. Bacterial and Plasmid Vectors Market Segmentation 4.1. Global Bacterial and Plasmid Vectors Market, Segmentation by Host Type, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global Bacterial and Plasmid Vectors Market, Segmentation by Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. Bacterial and Plasmid Vectors Market Regional and Country Analysis 5.1. Global Bacterial and Plasmid Vectors Market, Split by Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global Bacterial and Plasmid Vectors Market, Split by Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/9wb3wt

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read the original post:
Global Bacterial and Plasmid Vectors Market Report 2020: Market is Expected to Recover and Reach $0520 Million in 2023 at a CAGR of 15.48% - Forecast...

Posted in Genetic Engineering | Comments Off on Global Bacterial and Plasmid Vectors Market Report 2020: Market is Expected to Recover and Reach $0520 Million in 2023 at a CAGR of 15.48% – Forecast…

World-first echidna, improved platypus genomic sequencing – News – The University of Sydney

Posted: at 2:24 pm

Female platypuses dont have teats. Rather, they secrete milk onto their bellies for their babies to lap up. We believe that the novel antimicrobial peptide genes that we found are secreted by mothers through their milk, to protect their young from harmful bacteria while they are in burrows, Professor Belov said.

A similar process also occurs in echidnas. Newborn platypus and echidna do not have immune tissues or organs when they hatch from eggs. Their immune systems develop while they are in burrows.

These findings build on Professor Belovs prior, genomic research on the platypus, which pinpointed the genes responsible for the animals venom. Future work will involve measuring the antimicrobial activities of each platypus and echidna peptide against a broad panel of bacteria and viruses, to identify the best targets for future development.

Researchers from other Australian universities, including the University of Melbourne, focused on identifying and studying genes responsible for platypus lactation in order to understand mammals evolutionary transition from egg-laying to live birth.

Excerpt from:
World-first echidna, improved platypus genomic sequencing - News - The University of Sydney

Posted in Genome | Comments Off on World-first echidna, improved platypus genomic sequencing – News – The University of Sydney

Investing in Pacific Biosciences of California, Inc (NASDAQ:PACB) – Securities.io

Posted: at 2:09 pm

Pacific Biosciences of California, Inc (NASDAQ: PACB ) is a biotechnology company that produces DNA sequencing technology for use in a variety of scientific research purposes. Using Pacific Bioscience of California machines, scientists in laboratories around the world are able to rapidly and accurately observe DNA in real-time, allowing for access to a full spectrum of genetic information that was never before been available. As a relatively young company, their hardware and software developments have already led to several significant scientific advancements and as a result, Pacific Biosciences of California has become one of the most well-known names in the biotechnology space.

Based in Silicon Valley, Pacific Biosciences of California, Inc. (PacBio) is a biotechnology company that focuses on creating products and technologies that are used to advance genetic research. The company was founded by Dr. Stephen Turner in 2004 under the name Nanofluidics, Inc. before being renamed a few years later. After only a few short decades, the company has expanded to over 400 employees and boasts a wide range of products including sequencing machines, analytical software, and consumables, which are chemicals used in the process of converting DNA into a format that is ready to be read by sequencing machines.

The company operates in three main niches: plant and animal science, human biomedical research, and microbiology and infectious diseases. Using PacBio machines, plant and animal science research can be conducted on organisms as small as mosquitos that contain as little as 5 nanograms of DNA. Through the study of plant and animal genetics, PacBios technology fuels research that has been used to explore innovative ways of improving food and energy supply. Within the human biomedical science sector, research using PacBio products and services allows for the exploration of genetic variations to determine potential hidden hereditary causes of diseases. By being able to pinpoint epigenetic changes, the specific genetic variation that is behind diseases will be easier to understand. As this technology becomes more widely available due to lower costs, doctors will be able to improve the solve rate involved with diagnosing patients. Finally, PacBio machines are relied upon heavily for microbial and infectious diseases research, which has led to breakthroughs in finding cures and vaccines for a variety of viruses, bacteria, and other microbiotic organisms.

The company is well known for developing innovative technology to study DNA, RNA, and protein synthesis and regulation. In 2011, Pacific of California released its first product, PacBio RS, a DNA sequencing machine, into the market. The PacBio RS was the first machine that used Single-Molecule Real-Time (SMRT) sequencing technology. SMRT is a sequencing technology developed by PacBio that allows scientists to understand the inner workings of biological systems through real-time observation. The SMRT technology has the ability to sequence whole genomes or target specific sections of DNA/RNA. The technology also allows complex populations of bacteria, viruses, and other diseases to be tracked and responses to drug treatments to be observed. The two main advantages of PacBios SMRT sequencing machines over competitors are their low per-genome costs and high volume output. Upon the launch of their first product the PacBio RS, SMRT sequencing had the ability to read 1,110 bases, which are the smallest units of DNA. This technology underwent further innovation throughout the years, and the latest iteration, named the Sequel II system, now has the ability to read upwards of 500 million bases. For these advancements, PacBio and their Sequel II machine received an award from The Scientist for Top 10 Innovations in 2019.

These developments have made present-day DNA reading much faster and more cost-effective than any of its predecessors. The newest systems developed by PacBio also have reading accurate rates of over 99.9% accuracy, which is important to ensure trust and validity within the scientific community. Due to these benefits, this machine has become the first choice of scientists who seek highly accurate readings of large portions of DNA and other genetic material.

As genetic sequencing becomes more and more affordable, new uses for the technology are being discovered every day. PacBio estimates that 10 million human genetic sequences will be conducted annually by 2025 and that one day, the technology will become a routine part of healthcare. With trusted and reliable hardware and software, PacBio is well-positioned to continue its domination in terms of market share and remains a well-regarded partner for companies around the world.

The SMRT sequencing technology developed by PacBio is one of the best in the industry and has garnered interest from competitors. Illumina, another leader in the biotechnology sector, made a move to buy the company for $1.2 billion in 2018. The deal ultimately fell through, with both companies citing the lengthy regulatory approval process as the main reason for mutually agreeing to terminate the contract. Despite this, the interest from other companies shows the attractiveness of SMRT sequencing technology and the complementary role it could play for other emerging biotechnology innovations.

A broker that we recommend isFirstrade.

Firstrade is a leading online brokerage firm offering a full line of investment products and tools designed to help investors like you take control of your financial future. Since its founding in 1985, Firstrade has been committed to providing high value and quality services.

Combining proprietary trading technology, a highly intuitive user interface, outstanding customer service and mobile applications, Firstrade offers a comprehensive solution for all of your investing needs. Firstrade is a member of FINRA/SIPC.

As a company that has only been in existence for under two decades, the innovations made possible by the SMRT sequencing technology developed by PacBio have already had a lasting impact on the scientific community. As costs continue to drop, DNA sequencing has the potential to become a mainstream part of everyday healthcare. The potential market reach of this technology is nearly limitless. As a leader in the space, Pacific Biosciences of California is very well positioned to take advantage of the very promising future growth in the industry.

View original post here:
Investing in Pacific Biosciences of California, Inc (NASDAQ:PACB) - Securities.io

Posted in Human Genetics | Comments Off on Investing in Pacific Biosciences of California, Inc (NASDAQ:PACB) – Securities.io

Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health…

Posted: at 2:09 pm

"This study highlights a significant shift in how primary care physicians view DTC genetic health testing."

The report also found 80 percent of PCPs are open or likely to recommend DTC genetic testing for health if asked about it by their patients, and for 61 percent of PCPs, FDA oversight of health reports was a necessary element of any DTC genetic test they might recommend.

"This study highlights a significant shift in how primary care physicians view DTC genetic health testing," said L. Okey Onyejekwe Jr., MD, JD, Vice President of Healthcare Operations and Medical Affairs at 23andMe. "In just two year's time, the data show PCPs are much more accepting, and in some cases wholeheartedly embracing this type of testing, especially tests that include health reports with FDA oversight. As more consumers turn to DTC genetic testing for health insights into their genome, it's encouraging to see that PCPs are much more open to patients bringing their test results into the clinic for further discussion and potential follow up testing when warranted."

When it comes to all genetic testing, not just DTC genetic testing, 71 percent of PCPs are comfortable making appropriate referrals to specialists based on genetic information, compared to 44 percent in 2018. Further, 46 percent of PCPs are comfortable ordering genetic testing, a four-fold increase from 2018, and 41 percent are comfortable using genetic information to make treatment decisions, a two-fold increase over 2018.

"The shift in the primary care community's point of view on genetic testing over a relatively short period of time is striking, and points to the tests results having greater utility and impact in patient care," said Hansa Bhargava, M.D., Medscape Senior Medical Director. "We are pleased that we could contribute to increasing awareness of the role of genetic testing in the primary care environment."

Methodology

This report was completed by 1,000 U.S. primary care physicians on the Medscape platform between August 26, 2020 and September 14, 2020. Ninety percent of respondents practice Family or Internal medicine and respondents have practiced an average of 19 years. Respondents were invited to respond to the online survey. The margin of error at a 95% confidence level is +/- 3.0%. The report is a follow-up to a 2018 report on the same topic, which was completed by 1,000 U.S. primary care physicians on the Medscape platform between October 25, 2018 and November 22, 2018.

About Medscape

Medscape is the leading source of clinical news, health information, and point-of-care tools for health care professionals. Medscape offers specialists, primary care physicians, and other health professionals the most robust and integrated medical information and educational tools. Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free C.M.E. and C.E. courses and other educational programs for physicians, nurses, and other health care professionals. Medscape is a subsidiary of WebMD Health Corp.

About WebMD Health Corp.

WebMD Health Corp., an Internet Brands Company, is the leading provider of health information services, serving patients, physicians, health care professionals, employers, and health plans through public and private online portals, mobile platforms, and health-focused publications. The WebMD Health Network includes WebMD Health, Medscape, Jobson Healthcare Information, prIME Oncology, MediQuality, Frontline, Vitals Consumer Services, Aptus Health, MedicineNet, eMedicineHealth, RxList, OnHealth, Medscape Education, and other owned WebMD sites. WebMD, Medscape, CME Circle, Medpulse, eMedicine, MedicineNet, theheart.org, and RxList are among the trademarks of WebMD Health Corp. or its subsidiaries.

About 23andMe

23andMe, Inc. is the leading consumer genetics and research company. Founded in 2006, the mission of the company is to help people access, understand, and benefit from the human genome. 23andMe is the first direct-to-consumer company to receive FDA authorization for genetic health reports, and has millions of customers worldwide, with more than 80 percent of customers consented to participate in research. 23andMe, Inc. is located in Sunnyvale, CA. More information is available at http://www.23andMe.com.

SOURCE 23andMe

https://www.23andme.com/en-ca/

Original post:
Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health...

Posted in Human Genetics | Comments Off on Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health…

Gaucher Disease Treatment Market: Shows Increasing Demand To Be Observed In The Coming Decade | Genzyme Corporation, Pfizer, Inc., Shire Human…

Posted: at 2:09 pm

The Gaucher Disease Treatment Market Research Report is a resource, which provides current as well as upcoming technical and financial details of the industry to 2027. This report gives you so important and essentials data of Market size, share, trends, Growth, applications, forecast and cost analysis. Delivery development in North America, China, Europe, and South East Asia, Japan as well as in the Globe. The report proves to be indispensable when it comes to market definition, classifications, applications and engagements. The market report also computes the market size and revenue generated from the sales. The industry analysis report presents the key statistics on the market status of global and regional manufacturers and also acts as a valuable source of leadership and direction. What is more, theGaucher Disease Treatment market report analyses and provides historic data along with the current performance of the market

Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2, and type 3. Type 1 is the most common type of Gaucher disease while Type 2 and 3 are not as common as type 1.

This Press Release will help you to Know the Volume, growth with Impacting Trends. Get SAMPLE PDF (Including Full TOC, Table & Figures) at:

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/1225

Global Gaucher Disease Treatment Market competition by Top Key Players: Genzyme Corporation, Pfizer, Inc., Shire Human Genetics Therapies, Inc., and Actelion Pharmaceuticals Ltd. (acquired by Johnson & Johnson in June 2017). There are various drugs in pipeline of companies such as Lixte Biotechnology Holdings Inc, JCR Pharmaceuticals Co Ltd, Pharming Group NV and Orphazyme ApS, for Gaucher disease treatment.

Gaucher Disease Treatment Market section by Region:

The Middle East and Africa North AmericaSouth AmericaEuropeAsia-Pacific

Segmentation: The report has been separated into different categories, such as product type, application, end user, and region. Every segment is evaluated based on the CAGR, share and growth potential. In the regional analysis, the report highlights the prospective region, which should generate opportunities in the global Gaucher Disease Treatment market in the years to come. This segmented analysis will surely prove to be a useful tool for readers, stakeholders and market participants to get a full picture of the Gaucher Disease Treatment global market and its growth potential in the years to come.

TheGaucher Disease TreatmentMarket report offers a plethora of insights which include:

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/1225

Important Information that can be extracted from the Report:

Assessment of the COVID-19 impact on the growth of the Gaucher Disease Treatment MarketSuccessful market entry strategies formulated by emerging market playersPricing and marketing strategies adopted by established market playersCountry-wise assessment of the Gaucher Disease Treatment Market in key regionsYear-on-Year growth of each market segment over the forecast period 2026

TheGaucher Disease TreatmentMarket report considers the following years to predict market growth:

The GlobalGaucher Disease TreatmentMarket is displayed in 13 Chapters:

Chapter 1: Market Overview, Drivers, Restraints and OpportunitiesChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expensesChapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13:Gaucher Disease Treatment Research Findings and Conclusion, Appendix, methodology and data source

Original post:
Gaucher Disease Treatment Market: Shows Increasing Demand To Be Observed In The Coming Decade | Genzyme Corporation, Pfizer, Inc., Shire Human...

Posted in Human Genetics | Comments Off on Gaucher Disease Treatment Market: Shows Increasing Demand To Be Observed In The Coming Decade | Genzyme Corporation, Pfizer, Inc., Shire Human…

The Role of RNA Structure in Replication of Influenza and Coronaviruses – Imperial College London

Posted: at 2:09 pm

Please join us for the latest instalment of the Wright-Fleming Institute Infection and Immunity Seminar Series.

Dr David Bauer (Francis Crick Institute) will deliver a talk on The Role of RNA Structure in Replication of Influenza and Coronaviruses.

The seminar will be hosted via Microsoft Teams. All are welcome to attend.

David is a new group leader at the Francis Crick Institute, where he heads the RNA Virus Replication Laboratory. His work focuses on how virus RNA structure affects replication, transcription, and immune activation. Originally from New York, David carried out his doctoral work at the Wellcome Trust Centre for Human Genetics and received an NSF postdoctoral fellowship to study RNA polymerases and transcription using single-molecule methods with Achilles Kapanidis at Oxford. David then joined Ervin Fodors group at the Dunn School of Pathology in Oxford to study influenza virus transcription, combining his interests in genomics and RNA.

Join the meeting via Microsoft Teams

See the original post here:
The Role of RNA Structure in Replication of Influenza and Coronaviruses - Imperial College London

Posted in Human Genetics | Comments Off on The Role of RNA Structure in Replication of Influenza and Coronaviruses – Imperial College London

Leonid Bershidsky: Tech censorship is the real gift to Putin – TwinCities.com-Pioneer Press

Posted: at 2:06 pm

Alexey Navalny, the opposition leader whom the Russian secret police nearly killed with military-grade poison last year, is worried about Twitters decision to shut down Donald Trumps account. Navalny is no Trump fan; he is far to the left of the outgoing U.S. president. The reason he is worried is that the way U.S. tech has ganged up on Trump and his most radical supporters can lead to his own deplatforming in Russia, where he has no access to state-controlled media and relies on mostly U.S.-based social networks YouTube, Facebook, Twitter to spread his message. Thats a valid concern.

Navalny laid out his logic in an English-language Twitter thread. In my opinion, the decision to ban Trump was based on emotions and personal political preferences, he wrote. Dont tell me he was banned for violating Twitter rules. I get death threats here every day for many years, and Twitter doesnt ban anyone (not that I ask for it).

He added: Of course, Twitter is a private company, but we have seen many examples in Russian and China of such private companies becoming the states best friends and enablers when it comes to censorship. And, This precedent will be exploited by the enemies of freedom of speech around the world. In Russia as well. Every time when they need to silence someone, they will say: this is just common practice, even Trump got blocked on Twitter.

I cant say I was surprised to see American commentators jump in with condescending retorts telling Navalny that he doesnt get it, that he doesnt understand the importance of cracking down on insurrection or the right of private companies to police their platforms. The thing is, he nearly died defending Russians right to protest, and, as a corruption fighter, hes spent more than a decade delving into the shadowy relationships between private companies and the state. If he hasnt earned the right to be heard as an expert on such matters, I dont know who has.

The private company argument simply doesnt fly. Twitter and Facebook have tolerated Trump and his fans in all their glory calls for journalists to be murdered, racist bile, direct threats throughout the Trump presidency. Even if they said they didnt, the stuff was impossible to miss as a user of the social platforms. Apple, Google and Amazon allowed the censorship-free platform Parler, frequented by the far right, to grow using their services until two things happened: last weeks Capitol riot and the Georgia Senate elections that handed the Democrats full political control of the U.S.

I dont know which of the two was the actual deciding factor in the tech giants Trump crackdown. But look at it from the point of view of someone fighting an authoritarian regime in Russia, Turkey, Belarus or elsewhere. What youll see is the U.S. president-elect declaring protesters who broke into a government building domestic terrorists and an immediate response from the tech companies, which fall all over themselves trying to prove they arent providing terrorists with a platform. Are they suddenly outraged because a Democratic administration, in control of the House and Senate, can quickly regulate them in all kinds of painful ways? Seen from Russia, or Turkey or China, where concerns about politically motivated regulatory moves by single-party governments are top of mind for every business owner, this picture is familiar.

One could argue that even if U.S.-based tech platforms have rushed to align themselves with the political winners in their country to avoid a costly confrontation, they wont do the same for Russian President Vladimir Putin or his Turkish counterpart Recep Tayyip Erdogan. Its more complicated than that.

On paper, authoritarian regimes terrorism and insurrection laws are similar to those of the U.S. Now, the regimes have cover to demand from the U.S. networks that they ban Russian, Turkish, Belarussian domestic terrorists on the same grounds as the ones used against Trump and Trumpists inciting aggressive, violent protest. And if the platforms refuse, they will be accused of double standards, declared tools of the U.S. government and themselves harassed and possibly banned. That one-two combination wasnt possible before, because even authoritarians these days have to pay lip service to freedom of speech; what the platforms have done takes that concern out of the equation. Russian propagandists such as Margarita Simonyan, head of the RT channel, have long waited for such a golden opportunity to agitate for retaliation against U.S. platforms, ever since they started flagging content from Russian government-funded media.

Where would a Facebook, Twitter and YouTube ban leave people like Navalny? Theyd be confined to any start-up platforms that emerge to pick up the slack, and to Telegram, the Dubai-based platform created by Russian libertarian Pavel Durov, which the Russian government tried to block but failed, as Telegram fought back by ingenious technical means. But even for Telegram, which isnt U.S.-based, running uncensored content is dangerous these days like Parler, it could be thrown out of app stores, for example (although Telegram has been working on a full-featured mobile browser-based version for just such an eventuality).

The U.S. tech platforms, of course, werent set up to enable political opposition to authoritarian regimes. They are commercial enterprises that exist to make money by selling ads. Its probably a strategic mistake for any opposition figure in any country to put their eggs in this basket. But given the platforms oligopolistic nature, there hasnt been much choice.

In todays world, if a platform is to enable free speech, it needs to be technologically extraterritorial free from reliance on any providers sensitive to pressure from nation states. Both legally and financially, building such a platform is an enormous challenge. But then, I remember a time when authoritarian rulers failed despite banning private copy machines, let alone content platforms. Political opposition to flawed, unfree regimes will survive under any conditions, with or without Silicon Valley help; but it has likely suffered a setback. That, and not the unsuccessful riot at the Capitol, is the lasting gift to Putin. He wont fail to cash this check.

Leonid Bershidsky is a member of the Bloomberg News Automation team based in Berlin. He was previously Bloomberg Opinions Europe columnist. His Russian translation of George Orwells 1984 is due out in early 2021.

Visit link:
Leonid Bershidsky: Tech censorship is the real gift to Putin - TwinCities.com-Pioneer Press

Posted in Censorship | Comments Off on Leonid Bershidsky: Tech censorship is the real gift to Putin – TwinCities.com-Pioneer Press

Beyond Platforms: Private Censorship, Parler, and the Stack – EFF

Posted: at 2:06 pm

Last week, following riots that saw supporters of President Trump breach and sack parts of the Capitol building, Facebook and Twitter made the decision to give the president the boot. That was notable enough, given that both companies had previously treated the president, like other political leaders, as largely exempt from content moderation rules. Many of the presidents followers responded by moving to Parler. This week, the response has taken a new turn. Infrastructure companies much closer to the bottom of the technical stack including Amazon Web Services (AWS), and Googles Android and Apples iOS app storesdecided to cut off service not just to an individual but to an entire platform. Parler has so far struggled to return online, partly through errors of its own making, but also because the lower down the technical stack, the harder it is to find alternatives, or re-implement what capabilities the Internet has taken for granted.

Whatever you think of Parler, these decisions should give you pause. Private companies have strong legal rightsunder U.S. law to refuse to host or support speech they dont like. But that refusal carries different risks when a group of companies comes together to ensure that certain speech or speakers are effectively taken offline altogether.

To see the implications of censorship choices by deeper stack companies, lets back up for a minute. As researcher Joan Donovan puts it,At every level of the tech stack, corporations are placed in positions to make value judgments regarding the legitimacy of content, including who should have access, and when and how. And the decisions made by companies at varying layers of the stack are bound to have different impacts on free expression.

At the top of the stack are services like Facebook, Reddit, or Twitter, platforms whose decisions about who to serve (or what to allow) are comparatively visible, though still far too opaque to most users. Their responses can be comparatively targeted to specific users and content and, most importantly, do not cut off as many alternatives. For instance, a discussion forum lies close to the top of the stack: if you are booted from such a platform, there are other venues in which you can exercise your speech. These are the sites and services that all users (both content creators and content consumers) interact with most directly. They are also the places where people think of when they think of the content (i.e.I saw it on Facebook). Users are often required to have individual accounts or advantaged if they do. Users may also specifically seek out the sites for their content. The closer to the user end, the more likely it is that sites will have more developed and apparent curatorial and editorial policies and practicestheir "signature styles." And users typically have an avenue, flawed as it may be, to communicate directly with the service.

At the other end of the stack are internet service providers (ISPs), like Comcast or AT&T. Decisions made by companies at this layer of the stack to remove content or users raise greater concerns for free expression, especially when there are few if any competitors. For example, it would be very concerning if the only broadband provider in your area cut you off because they didnt like what you said onlineor what someone else whose name is on the account said. The adage if you dont like the rules, go elsewhere doesnt work when there is nowhere else to go.

In between are a wide array of intermediaries, such as upstream hosts like AWS, domain name registrars, certificate authorities (such as Lets Encrypt), content delivery networks (CDNs), payment processors, and email services. EFF has a handy chart of some of those key links between speakers and their audience here. These intermediaries provide the infrastructure for speech and commerce, but many have only the most tangential relationship to their users. Faced with a complaint, takedown will be much easier and cheaper than a nuanced analysis of a given users speech, much less the speech that might be hosted by a company that is a user of their services. So these service are more likely to simply cut a user or platform off than do a deeper review. Moreover, in many cases both speakers and audiences will not be aware of the identities of these services and, even if they are, have no independent relationship with them. These services are thus not commonly associated with the speech that passes through them and have no "signature style" to enforce.

We saw a particularly egregious example of an infrastructure takedown just a few months ago, when Zoom made the decision to block a San Francisco State University online academic event featuring prominent activists from Black and South African liberation movements, the advocacy group Jewish Voice for Peace, and controversial figure Leila Khaledinspiring Facebook and YouTube to follow suit. The decision, which Zoom justified on the basis of Khaleds alleged ties to a U.S.-designated foreign terrorist organization, was apparently made following external pressure.

Although we have numerous concerns with the manner in which social media platforms like Facebook, YouTube, and Twitter make decisions about speech, we viewed Zooms decision differently. Companies like Facebook and YouTube, for good or ill, include content moderation as part of the service they provide. Since the beginning of the pandemic in particular, however, Zoom has been used around the world more like a phone company than a platform. And just as you dont expect your phone company to start making decisions about who you can call, you dont expect your conferencing service to start making decisions about who can join your meeting.

Just as you dont expect your phone company to start making decisions about who you can call, you dont expect your conferencing service to start making decisions about who can join your meeting.

It is precisely this reason that Amazons ad-hoc decision to cut off hosting to social media alternative Parler, in the face of public pressure, should be of concern to anyone worried about how decisions about speech are made in the long run. In some ways, the ejection of Parler is neither a novel, nor a surprising development. Firstly, it is by no means the first instance of moderation at this level of the stack. Prior examples include Amazon denying service to WikiLeaks and the entire nation of Iran. Secondly, the domestic pressure on companies like Amazon to disentangle themselves from Parler was intense, and for good reason. After all, in the days leading up to its removal by Amazon, Parler played host to outrageously violent threats against elected politicians from its verified users, including lawyer L. Lin Wood.

But infrastructure takedowns nonetheless represent a significant departure from the expectations of most users. First, they are cumulative, since all speech on the Internet relies upon multiple infrastructure hosts. If users have to worry about satisfying not only their hosts terms and conditions but also those of every service in the chain from speaker to audienceeven though the actual speaker may not even be aware of all of those services or where they draw the line between hateful and non-hateful speechmany users will simply avoid sharing controversial opinions altogether. They are also less precise. In the past, weve seen entire large websites darkened by upstream hosts because of a complaint about a single document posted. More broadly, infrastructure level takedowns move us further toward a thoroughly locked-down, highly monitored web, from which a speaker can be effectively ejected at any time.

Going forward, we are likely to see more cases that look like Zooms censorship of an academic panel than we are Amazon cutting off another Parler. Nevertheless, Amazons decision highlights core questions of our time: Who should decide what is acceptable speech, and to what degree should companies at the infrastructure layer play a role in censorship?

At EFF, we think the answer is both simple and challenging: wherever possible, users should decide for themselves, and companies at the infrastructure layer should stay well out of it. The firmest, most consistent, approach infrastructure chokepoints can take is to simply refuse to be chokepoints at all. They should act to defend their role as a conduit, rather than a publisher. Just as law and custom developed a norm that we might sue a publisher for defamation, but not the owner of the building the publisher occupies, we are slowly developing norms about responsibility for content online. Companies like Zoom and Amazon have an opportunity to shape those normsfor the better or for the worse.

Its easy to say today, in a moment of crisis, that a service like Parler should be shunned. After all, people are using it to organize attacks on the U.S. Capitol and on Congressional leaders, with an expressed goal to undermine the democratic process. But when the crisis has passed, pressure on basic infrastructure, as a tactic, will be re-used, inevitably, against unjustly marginalized speakers and forums. This is not a slippery slope, nor a tentative predictionwe have already seen this happen to groups and communities that have far less power and resources than the President of the United States and the backers of his cause. And this facility for broad censorship will not be lost on foreign governments who wish to silence legitimate dissent either. Now that the world has been reminded that infrastructure can be commandeered to make decisions to control speech, calls for it will increase: and principled objections may fall to the wayside.

Over the coming weeks, we can expect to see more decisions like these from companies at all layers of the stack. Just today, Facebook removed members of the Ugandan government in advance of Tuesdays elections in the country, out of concerns for election manipulation. Some of the decisions that these companies make may be well-researched, while others will undoubtedly come as the result of external pressure and at the expense of marginalized groups.

The core problem remains: regardless of whether we agree with an individual decision, these decisions overall have not and will not be made democratically and in line with the requirements of transparency and due process, and instead are made by a handful of individuals, in a handful of companies, most distanced and least visible to the most Internet users. Whether you agree with those decisions or not, you will not be a part of them, nor be privy to their considerations. And unless we dismantle the increasingly centralized chokepoints in our global digital infrastructure, we can anticipate an escalating political battle between political factions and nation states to seize control of their powers.

More:
Beyond Platforms: Private Censorship, Parler, and the Stack - EFF

Posted in Censorship | Comments Off on Beyond Platforms: Private Censorship, Parler, and the Stack – EFF

Both sides: The debate over social media and censorship – wreg.com

Posted: at 2:06 pm

by: Rob Nelson, Nexstar Media Wire

CHICAGO (NewsNation Now) Snapchat is banning President Donald Trump, the latest in a line of suspensions and bans from the likes of YouTube, Facebook and Instagram.

The moves have ignited a debate over social media and censorship. NewsNation spoke with people on both sides of the issue.

MIT media professor Ethan Zuckerman said social media sites are within their rights to ban users who dont follow their policies.

That said, more broadly, Im not thrilled about this idea of how much control Facebook and Twitter have of anyones speech, said Zuckerman.

We also spoke with UCLA law professor Eugene Volokh about the social media de-platforming of President Trump.

He thinks private companies like Twitter have a right to ban users, but that banning an elected official with a large following may be an excessive use of their power.

Im not saying that Twitter violated its own policies. Its hard to tell because the process is not transparent. Its not like the courts where you have all these court records, Volokh said.

Both people NewsNation interviewed, while falling on different sides of the debate, still are seemingly in agreement on wondering if social media companies have too much influence in public discourse in America.

Watch the full conversation and a look at both sides of this issue in the player above.

President Donald Trump in his White House video on Wednesday night condemned the social media bans, calling them an assault on free speech. He said Americans should listen to each other, not silence each other.

Read more from the original source:
Both sides: The debate over social media and censorship - wreg.com

Posted in Censorship | Comments Off on Both sides: The debate over social media and censorship – wreg.com

Page 1,119«..1020..1,1181,1191,1201,121..1,1301,140..»